The Ministry of Industry and Trade recently announced its decision to recognize 499 products from 227 enterprises as achieving "Vietnam National Brand 2026" status in late August. These represent outstanding, high-quality products from companies that meet stringent criteria for quality, innovation, and leading capabilities.

Among the recognized entities, Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company (Bidiphar) from Gia Lai province received certification for five products. These include three cancer treatment drugs, one line of hemodialysis solutions, and one anti-inflammatory and immunosuppressant drug.

A Bidiphar representative stated that the company's cancer treatment drugs, kidney dialysis solutions, and tablet medications are widely used in medical facilities and pharmacies. These products address treatment needs at affordable costs, significantly contributing to the company's revenue and establishing themselves as core products.

Day chuyen san xuat thuoc dieu tri ung thu cua Bidiphar. Anh: Bidiphar

Alongside advanced manufacturing technology, Bidiphar invests heavily in research and development, laboratory modernization, and digital transformation. The company implemented SAP-ERP in 2014 and utilizes systems such as DMS and Power BI, gradually integrating artificial intelligence into its management operations. These systems aim to connect data from production and distribution to overall management, helping the company enhance operational efficiency and make data-driven decisions. This strategic direction also extends to developing raw material sources, fostering international cooperation, and investing in high-tech drug lines to progressively replace imported products.

According to Bidiphar's leadership, the company aims to become one of the top 3 most reputable pharmaceutical manufacturers in Vietnam by 2030, achieving 3,000 billion VND in revenue. It also targets acquiring GMP-EU certified production lines, focusing on developing high-quality pharmaceutical products.

Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company (Bidiphar) operates in the pharmaceutical and medical equipment sectors. It originated from Nghia Binh Pharmaceutical Enterprise II, established in 1980. In 1995, the enterprise merged with Binh Dinh Pharmaceutical and Medical Supplies Company, adopting the name Binh Dinh Pharmaceutical and Medical Equipment Company. Bidiphar develops various product groups, including cancer treatment drugs, hemodialysis solutions, cardiovascular drugs, digestive aids, and vitamins. The company also invests in production lines that meet international standards. In 2014, the enterprise transitioned to a joint-stock company model. Currently, Bidiphar operates a robust production and distribution system serving the domestic market while also exporting some products internationally.

Hai My